A Phase 1/2a Multicenter Open-Label Non-Randomized First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors.

Brief description of study

You can participate in this study If you are diagnosed with HER2-positive or HER2-expressing advanced/unresectable, recurrent tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available. The purpose of this study is to assess the safety, tolerability, efficacy and, anti-tumor activity of the study drug (DB-1303) in patients with advanced/metastatic solid tumors. The study is also being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on this medication during the entire study period.


Clinical Study Identifier: s22-00655
ClinicalTrials.gov Identifier: NCT05150691
Principal Investigator: Whitfield B. Growdon.
Other Investigators: Kent Chan, Jaime Lynn Moyles, Nitish Mehta, Deanna Gerber, Eva Chalas-Westermann, Olivia Richardson Khouri, Laura Palazzolo, Marina Stasenko, Jonathan B Kahn, Fabia Brisard Pierrot, Caitlin Elizabeth Ryan, Leslie R Boyd, Christina Grace Wilson, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Carol M Lee, Bhavana Pothuri, Edward A Jimenez, Erin Annette Reese, Gabrielle Fridman, Kelly A Levine, Kathleen M Lutz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.